Cardiovasc Diabetol by MOHAMMEDI, Kamel et al.
Mohammedi et al. Cardiovasc Diabetol            (2021) 20:3  
https://doi.org/10.1186/s12933-020-01198-y
ORIGINAL INVESTIGATION
History of lower-limb complications and risk 
of cancer death in people with type 2 diabetes
Kamel Mohammedi1,2,3* , Stephen Harrap4, Giuseppe Mancia5, Michel Marre6,7,8, Neil Poulter9, 
John Chalmers10,11 and Mark Woodward10,11,12,13
Abstract 
Background: Individuals with diabetes and lower-limb complications are at high risk for cardiovascular and all-cause 
mortality, but uncertainties remain in terms of cancer-related death in this population. We investigated this relation-
ship in a large cohort of people with type 2 diabetes.
Methods: We used data from the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release 
Controlled Evaluation (ADVANCE) study. The primary outcome was adjudicated cancer death; secondary outcomes 
were overall and site-specific incident cancers, determined according to the International Classification of Diseases 
Code (ICD-10). We compared outcomes in individuals with (versus without) a baseline history of lower-limb complica-
tions (peripheral artery disease (PAD) or sensory peripheral neuropathy) using Cox regression models.
Results: Among 11,140 participants (women 42%, mean age 66 years), lower-limb complications were reported at 
baseline in 4293 (38%) individuals: 2439 (22%) with PAD and 2973 (27%) with peripheral neuropathy. Cancer death 
occurred in 316 (2.8%) participants during a median of 5.0 (25th–75th percentile, 4.7–5.1) years of follow-up cor-
responding to 53,550 person-years and an incidence rate of 5.9 (95% CI 5.3–6.6) per 1000 person-years. The risk of 
cancer death was higher in individuals with (versus without) lower-limb complication [hazard ratio 1.53 (95% CI, 
1.21–1.94), p = 0.0004], PAD [1.32 (1.02–1.70), p = 0.03] or neuropathy (1.41 (1.11–1.79), p = 0.004], adjusting for poten-
tial confounders and study allocations. PAD, but not neuropathy, was associated with excess risk of incident cancers.
Conclusions: PAD and peripheral neuropathy were independently associated with increased 5-year risk of cancer 
death in individuals with type 2 diabetes. PAD was also associated with increased risk of incident cancers. Our findings 
provide new evidence on the non-cardiovascular prognostic burden of lower-limb complications in people with type 
2 diabetes.
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Background
Peripheral artery disease (PAD) and peripheral sensory 
neuropathy are major lower-limb complications fre-
quently observed in patients with diabetes [1–5]. These 
are the leading causes of non-traumatic lower-extremity 
amputation, at least 8 times more common in people 
with diabetes than in persons without diabetes [6, 7]. 
Lower-limb complications are associated with major 
disability, worsening quality of life and huge impacts on 
health care systems and societies [1, 8, 9]. They are also 
associated with a dramatic reduction in life expectancy, 
despite major improvements in medical care during 
recent decades [3, 10–13]. The excess risk of premature 
death observed in patients with diabetes and lower-
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to cardiovascular disease, as other non-cardiovascular 
conditions may also be involved [14].
Cancer is a major public health problem worldwide, 
and is the second leading cause of death [15]. Grow-
ing data suggest an excess risk for cancer death among 
adults with diabetes, compared with others [16–19]. 
The risk of cancer increased in people with cardiovas-
cular disease as did the risk of cardiovascular disease 
in cancer patients [20]. Only few studies have evaluated 
the risk for cancer death according to vascular com-
plications in people with diabetes, and have reported 
inconsistent findings [21–23]. As far as we are aware, 
the relationship between lower-limb complications 
and cancer death has not been investigated in patients 
with diabetes. In the present study, we aimed to evalu-
ate the incidence and the relative risk of cancer death 
according to the baseline history of lower-limb com-
plications among patients with type 2 diabetes in the 
Action in Diabetes and Vascular Disease: PreterAx and 




ADVANCE was a large multicentre international rand-
omized trial conducted in patients with type 2 diabetes 
to test the effects of intensive glucose control using a 
gliclazide-MR based regimen and blood pressure treat-
ment using a fixed-dose combination of perindopril and 
indapamide on the incidence of major microvascular 
and macrovacular events [24]. The design and clinical 
characteristics of participants in ADVANCE have been 
published previously [24–26]. Briefly, patients with 
type 2 diabetes mellitus, and at least one additional 
risk factor for cardiovascular disease, were randomly 
assigned in a 2 X 2 factorial design to: (i) gliclazide 
(modified release)–based intensive glucose-control 
regimen, targeting an HbA1c of ≤ 6.5%, or to stand-
ard glucose control, with targets and regimens based 
on local guidelines, and (ii) a fixed-dose combination 
of perindopril (4  mg) and indapamide (1.25  mg) or 
matching placebo. Participants were enrolled between 
2001 and 2003; they were seen 3, 4, and 6 months after 
randomisation, and subsequently, every 6 months until 
June 2007 (for blood-pressure–lowering comparison) 
[25]. The follow-up in the randomized glucose-control 
regimen was continued for an additional 6  months, 
until January 2008 with a different follow-up schedule 
as published previously [25, 26]. The protocol of the 
ADVANCE trial was approved by the Institutional Eth-
ics Committee of each participating centre and all par-
ticipants provided written informed consent.
Definition of lower‑limb complications at baseline
A history of lower-limb complication was defined as the 
presence at baseline of PAD or peripheral neuropathy. 
PAD was defined as the presence of at least one of fol-
lowing conditions: lack of peripheral pulse (dorsalis pedis 
or posterior tibial) palpation, requirement of lower-limb 
revascularisation (surgery, angioplasty or emergency 
thrombolysis), or lower-extremity amputation of at least 
one digit, thought to be due to arterial insufficiency. 
Peripheral sensory neuropathy was defined as the pres-
ence at baseline of at least two neurological abnormalities 
[27]: disturbance of the light touch sensation, abolition 
of ankle or knee reflex or chronic (at least 6 weeks) foot 
ulceration. Data were collected by physicians for each 
participant based on interview and clinical examination, 
and reported in the case report forms.
Definition of other conditions at baseline
History of coronary artery disease (CAD) was defined as 
the presence at baseline of at least myocardial infarction, 
coronary artery bypass graft, percutaneous transluminal 
coronary angioplasty, or hospital admission for unstable 
angina. History of cerebrovascular disease was defined as 
the presence at baseline of stroke or transient ischaemic 
attack. Diabetic retinopathy was defined as the presence 
of at least one of the following conditions: prolifera-
tive retinopathy, macular oedema, requirement of reti-
nal laser photocoagulation therapy, or diabetes-related 
blindness. History of diabetic kidney disease (DKD) 
was defined as urinary albumin-to-creatinine ratio 
(ACR) > 30 µg/mg or estimated glomerular filtration rate 
(eGFR, computed using the Chronic Kidney Disease Epi-
demiology Collaboration equation) < 60 ml/min/1.73 m2.
Region of origin was categorized as 3 groups: Asia 
(Philippines, China, Malaysia, and India), established 
market economies (Australia, Canada, France, Germany, 
Ireland, Italy, Netherlands, New Zealand, and United 
Kingdom) and Eastern Europe (the Czech Republic, Esto-
nia, Hungary, Lithuania, Poland, Russia, and Slovakia). 
Cognitive function was estimated by the mini-mental 
state examination (MMSE) score and considered as nor-
mal (MMSE score ≥ 28) or reduced (MMSE score < 28). 
Education accomplishment was defined as age at comple-
tion of the highest level of formal education, and catego-
rized as basic (≥ 16 years) or low (≤ 15 years).
Primary and secondary endpoints
The primary endpoint for this analysis was cancer death 
occurring during follow-up. The cause of each death, 
including cancer-related death, was adjudicated by an 
independent endpoint committee, blinded to study allo-
cations. The adjudication committee reviewed source 
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documentations for all individuals who died during 
follow-up. The secondary endpoints were overall and 
site-specific incident cancers, defined as the first cancer 
diagnosed after entry to the study according to the Inter-
national Classification of Diseases Code Tenth Revision 
(ICD-10). Diagnostic codes used in the study are pre-
sented in Additional file  1: Table  S1. Incident cancers 
were collected systematically for all participants during 
the scheduled study visits from case report forms, and 
from reports of serious adverse events, without adjudi-
cation. Information about the occurrence of all serious 
adverse events was reported at the time of occurrence 
between visits. When serious adverse events occurred, 
the responsible investigator of each centre ensured that 
the event was reported immediately by completing a 
Serious Adverse Events Form. The Data and Safety Moni-
toring Committee regularly reviewed all such events for 
each centre. The effect of intensive (versus conventional) 
glucose control on cancer death in ADVANCE has been 
previously reported [28].
Statistical analyses
Quantitative variables were expressed as mean (SD), or 
median (25th, 75th percentiles) for those with skewed 
distributions. Categorical parameters were expressed as 
numbers and percentages.
Cox proportional hazards regression models were used 
to estimate hazard ratios (HR) and their 95% confidence 
intervals (CI) for risk of outcomes according to our three 
index exposures. We compared the incidence of cancer 
death according to study allocations: perindopril/indapa-
mide combination (versus placebo) or both intensive glu-
cose control and active blood pressure treatment (versus 
standard glucose control and placebo group).
Kaplan–Meier curves were used to plot the cumulative 
incidence of cancer death during follow-up according to 
the baseline history of lower-limb complication, PAD or 
peripheral neuropathy at baseline. Survival curves were 
compared using the log-rank test. Cox proportional haz-
ards regression models were fitted to estimate the risk 
of outcomes during follow-up according to the history 
of lower-limb complication at baseline. Analyses were 
adjusted for baseline age, sex, region of origin and study 
allocations (model 1), and for model 1 plus any poten-
tial confounders: duration of diabetes, body mass index, 
waist circumference, systolic and diastolic blood pres-
sure, HbA1c, urinary ACR, eGFR, total cholesterol, HDL 
cholesterol, triglycerides, MMSE score, education accom-
plishment, history of ever or current smoking, history of 
past or current alcohol drinking, history of CAD, cer-
ebrovascular disease, diabetic retinopathy or dementia, 
and use of metformin, insulin, antihypertensive, statins 
or antiplatelet therapies (model 2). Continuous variables 
supposed to have U-shaped relationships with death (age, 
body mass index, waist circumference, systolic and dias-
tolic blood pressure, HbA1c, and eGFR) were introduced 
within the model with their squared values.
We tested for interaction between PAD and peripheral 
neuropathy in their association with cancer death. The 
proportional hazards assumption was checked using the 
Schoenfeld residuals method.
We performed a series of sensitivity analyses to evalu-
ate the risks of endpoints according to: 1/ the history of 
lower-limb complications at baseline using an alterna-
tive definition of lower-limb complications: the presence 
of at least one of the following conditions: PAD (lack of 
peripheral pulse palpation or requirement of lower-limb 
revascularisation), peripheral neuropathy (at least two 
neurological abnormalities: disturbance of the light touch 
sensation, abolition of ankle or knee reflex), or tissue or 
limb loss (foot ulceration or lower-extremity amputa-
tion); 2/ peripheral neuropathy defined alternatively 
as the presence of at least one neurological abnormal-
ity (disturbance of the light touch sensation, abolition 
of ankle reflex or abolition of knee reflex) or a history of 
foot ulceration. We evaluated the associations between 
lower-limb complications and the risk of cancer death in 
people who have smoked cigarettes regularly (most days 
for at least a year) and those who have never smoked. 
Also, we tested the association between lower-limb com-
plications and the risk of cardiovascular and all-cause 
death. Finally, we used the Fine and Gray method to esti-
mate the subdistribution Hazard ratio for cancer death, 
while accounting for the competing risk of death from 
non-cancer causes further to adjusting as in model 2 [29].
Statistics were performed using SAS software, version 
9.3 (SAS Institute, Cary, NC, USA, www.sas.com) and 
Stata software version 15.1 (StataCorp, TX, USA, http://




Among 11,140 ADVANCE participants, 4733 (42%) were 
women, 4136 (37%) from Asia, 4862 (44%) from estab-
lished market economies and 2142 (19%) from eastern 
Europe. Their mean (SD) age and duration of diabetes 
were 66 (6) and 7.9 (6.3) years, respectively, and the mean 
(SD) HbA1c was 7.5 (1.6%) at baseline (Table 1). A his-
tory of lower-limb complication was reported at baseline 
in 4293 (38%) participants: 2439 (22%) with PAD and 
2973 (27%) with peripheral neuropathy. PAD and periph-
eral neuropathy were present simultaneously in 1119 
(10%) individuals. Characteristics of participants accord-
ing to a history of PAD or peripheral neuropathy at base-
line are displayed in Table 1.
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Table 1 Characteristics of  participants according to  history of  peripheral artery disease or  peripheral neuropathy 
at baseline
Overall Peripheral artery disease Peripheral neuropathy
No Yes No Yes
Number 11,140 8701 2439 (22) 8167 2973 (27)
Gender, n (%)
 Women 4733 (42) 3816 917 (19) 3580 1153 (24)
 Men 6407 (58) 4885 1522 (24) 4587 1820 (28)
Region of origin, n (%)
 Asia 4136 (37) 3755 381 (9) 3426 710 (17)
 Established market economies 4862 (44) 3225 1637 (34) 3260 1602 (33)
 Eastern Europe 2142 (19) 1721 421 (20) 1481 661 (31)
Age, years: mean (SD) 66 (6) 65 (6) 67 (7) 65 [6] 67 (7)
Duration of diabetes, years: mean (SD) 7.9 (6.3) 7.8 (6.2) 8.4 (6.8) 7.6 (6.2) 8.7 (6.6)
Body mass index, kg/m2: mean (SD) 28 (5) 28 (5) 29 (5) 28 (5) 29 (6)
Waist circumference, cm: mean (SD) 98 (13) 98 (13) 102 (13) 97 (13) 102 (13)
Systolic blood pressure, mmHg: mean (SD) 145 (21) 145 (21) 146 (21) 145 (21) 146 (21)
Diastolic blood pressure, mmHg: mean (SD) 81 (11) 81 (11) 80 (10) 81 (11) 80 (11)
Mini-mental state examination
 Overall MMSE score, mean (SD) 28 (2) 29 (2) 28 (2) 29 (2) 28 (2)
 Participants with normal MMSE score, n (%) 8689 (78) 6900 1789 (21) 6480 2209 (25)
 Participants with reduced MMSE score, n (%) 2451 (22) 1801 650 (27) 1687 764 (31)
Education accomplishment
 Age at completion, years: mean (SD) 18 (7) 19 (7) 18 (7) 19 (7) 18 (7)
 Participants with basic education, n (%) 7116 (64) 5809 1307 (18) 5402 1714 (24)
 Participants with low education, n (%) 4024 (36) 2892 1132 (28) 2765 1259 (31)
HbA1c, mean (SD)
 (%) 7.5 (1.6) 7.5 (1.6) 7.4 (1.4) 7.5 (1.6) 7.5 (1.5)
 mmol/mol 59 (17) 59 (17) 58 (15) 59 (17) 59 (16)
Urinary ACR, µg/mg: median  (25th,  75th percentiles) 1 (1,2) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0) 1.0 (1.0, 2.0)
eGFR, ml/min/1.73m2: mean (SD) 74 (17) 75 (17) 71 (18) 75 (18) 72 (17)
Serum total cholesterol, mmol/l: mean (SD) 5.2 (1.2) 5.2 (1.2) 5.0 (1.1) 5.2 (1.2) 5.1 (1.2)
Serum HDL cholesterol, mmol/l: mean (SD) 1.2 (0.3) 1.3 (0.3) 1.2 (0.3) 1.3 (0.4) 1.2 (0.3)
Serum LDL cholesterol, mmol/l: mean (SD) 3.1 (1.0) 3.1 (1.0) 3.0 (1.0) 3.1 (1.0) 3.0 (1.0)
Serum triglycerides, mmol/l: median (25th, 75th percentiles) 1.6 (1.2, 2.3) 1.6 (1.2, 2.3) 1.6 (1.2, 2.3) 1.6 (1.2, 2.3) 1.6 (1.2, 2.3)
History of complications, n (%)
 Coronary arterial disease 2380 (21) 1694 686 (29) 1611 769 (32)
 Cerebrovascular disease 1439 (13) 1107 332 (23) 1099 340 (24)
 Diabetic kidney disease 2444 (22) 1771 673 [28] 1699 745 (30)
 Diabetic retinopathy 1079 (10) 812 267 (25) 748 331 (31)
 Dementia 109 (1) 75 34 (31) 67 42 (39)
History of tobacco smoking, n (%)
 Ever 4674 (42) 3303 1371 (29) 3216 1458 (31)
 Current 1682 (15) 1287 395 (23) 1212 470 (28)
History of alcohol drinking, n (%)
 Past 4237 (38) 3015 1222 (29) 2997 1240 (29)
 Current 3396 (30) 2433 963 (28) 2368 1028 (30)
History of medication use, n (%)
 Metformin 6752 (61) 5238 1514 (22) 4836 1916 (28)
 Insulin therapy 159 (1) 133 26 (16) 118 41 (26)
 Antihypertensive treatment 7655 (69) 5908 1747 (23) 5552 2103 (27)
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Incidence of cancer death
Cancer death occurred in 316 (2.8%) participants dur-
ing a median of 5.0  (25th–75th percentile, 4.7–5.1) years 
of follow-up corresponding to 53,550 person-years and 
an incidence rate of 5.9 (95% CI 5.3–6.6) per 1000 per-
son-years. The cumulative incidence of cancer death was 
2.1% in women and 3.4% in men. The baseline mean (SD) 
age, duration of diabetes, HbA1c, systolic and diastolic 
blood pressure of individuals who subsequently died 
from cancer causes were 69 (6) years, 7.9 (6.6) years, 7.6 
(6.6%), 146 (22) mmHg and 80 (11) mmHg, respectively 
(Table 2). Hazard ratio for cancer death according to each 
individual parameter is shown in Table 3, after adjusting 
for study allocations.
Effects of study treatments on the risk for cancer death
Cancer death occurred in 147 (2.6%) participants 
assigned to perindopril/indapamide combination ver-
sus 169 (3.0%) individuals assigned to placebo (inci-
dence rate: 5.5 [95% CI, 4.6—6.4] versus 6.3 [5.4—7.4] 
per 1000 person-years) with no significant difference 
between blood pressure treatment groups: HR 0.86 (95% 
CI, 0.69–1.08). Cancer death occurred in 65 (2.3%) par-
ticipants [incidence rate 4.8 (3.8–6.2) per 1000 person-
years] randomized to both intensive glucose control and 
active blood pressure treatment versus 86 (3.1%) individ-
uals [incidence rate 6.4 (5.2–8.0) per 1000 person-years] 
assigned to standard glucose control and placebo group 
[HR 0.75 (0.54–1.03)].
Risk of cancer death according to history of lower‑limb 
complications at baseline
The cumulative incidences (Table 4 and Fig. 1) and inci-
dence rates of cancer death were higher in participants 
with a baseline history of lower-limb complications [8.3 
(95% CI, 7.2–9.7] vs. 4.4 (3.7–5.2) per 1000 person-years], 
PAD [8.9 (7.3–10.8) vs. 5.1 (4.4–5.8) per 1000 person-
years] or peripheral neuropathy [8.4 (7.1–10.1) vs. 5.0 
[4.3–5.7] per 1000 person-years), compared with individ-
uals without this complication. The risk of cancer death 
was higher in patients with a baseline history of lower-
limb complication [HR 1.62 (1.29–2.04), p < 0.0001], 
PAD [1.43 (1.12–1.83), p = 0.004] or peripheral neuropa-
thy [1.49 (1.19–1.88), p = 0.0006], compared with those 
without these conditions after adjusting for age (and its 
square), sex, region of origin and study allocations. These 
associations remained significant after further adjust-
ment for a wide range of potential confounders (model 
2, Table  4). When we used our alternative definition of 
lower-limb complication, PAD and peripheral neuropa-
thy remained associated with increased risk of cancer 
death, but not the history of tissue or limb loss (Addi-
tional file  1: Table  S2). Comparable results were also 
observed when peripheral neuropathy was defined as 
the presence of at least one neurological abnormality or 
a history of foot ulceration (Additional file 1: Table S3). 
Associations between lower-limb complications and 
risk of cancer death were comparable when were strati-
fied analyses by smoking status, with no evidence for 
statistical interaction (Additional file  1: Table  S4). No 
statistical interaction was observed between PAD and 
peripheral neuropathy in their association with cancer 
death (p = 0.14).
Risk of cancer death according to baseline history 
of lower‑limb complications considering death 
from non‑cancer causes as a competing risk
All-cause and cardiovascular death occurred in 1031 
(9.2%) and 542 (4.9%) participants during follow-up. 
Their incidence rates were 19.2 (95% CI 18.1–20.5) and 
10.1 (9.3–11.0) per 1000 person-years, respectively. We 
observed an increased risk of all-cause and cardiovascu-
lar death in patients with a baseline history of lower-limb 
complications or PAD, compared with those without 
these complications (Additional file  1: Table  S5). The 
history of peripheral neuropathy was associated with 
Table 1 (continued)
Overall Peripheral artery disease Peripheral neuropathy
No Yes No Yes
 Antiplatelet drugs 5199 (47) 3914 1285 [25] 3694 1505 (29)
 Statins 3146 (28) 2207 939 (30) 2121 1025 [33]
Study allocations, n (%)
 Intensive glucose control group 5571 (50) 4334 1237 (22) 4063 1508 (27)
 Perindopril/indapamide combination 5569 (50) 4365 1204 (22) 4070 1499 (27)
Categorical parameters are expressed as numbers (and percentages for participants with baseline history of PAD or peripheral neuropathy). ACR albumin to creatinine 
ratio. eGFR estimated Glomerular Filtration Rate computed by the Chronic Kidney Disease Epidemiology Collaboration equation. Mini-Mental State Examination 
(MMSE) score: normal (≥ 28), reduced (< 28). Education accomplishment (age at completion of the highest level of formal education): basic (≥ 16 years), low 
(≤ 15 years)
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Table 2 Characteristics of participants at baseline according to the incidence of cancer death during follow-up
Cancer death
No Yes
N 10,824 316 (2.8)
Gender, n (%)
 Women 4633 100 (2.1)
 Men 6191 216 (3.4)
Region of origin, n (%)
 Asia 4059 77 (1.9)
 Established market economies 4688 174 (3.6)
 Eastern Europe 2077 65 (3.0)
Age, years: mean (SD) 66 (6) 69 (6)
Duration of diabetes, years: mean (SD) 7.9 (6.3) 7.9 (6.6)
Body mass index, kg/m2: mean (SD) 28 (5) 29 (5)
Waist circumference, cm: mean (SD) 98 (13) 101 (13)
Systolic blood pressure, mmHg: mean (SD) 145 (21) 146 (22)
Diastolic blood pressure, mmHg: mean (SD) 81 [11] 80 [11]
Mini-mental state examination
 Overall MMSE score, mean (SD) 28 (2) 28 (2)
 Participants with normal MMSE score, n (%)  8456 233 (2.7)
 Participants with reduced MMSE score, n (%) 2368 83 (3.4)
Education accomplishment
 Age at completion, years: mean (SD) 18 (7) 17 (6)
 Participants with basic education, n (%) 6941 175 (2.5)
 Participants with low education, n (%) 3883 141 (3.5)
HbA1c, mean (SD)
 % 7.5 (1.5) 7.6 (1.6)
 mmol/mol 59 (17) 59 (17)
Urinary ACR, µg/mg: median (25th, 75th percentiles) 1 (1,2) 1 (1,2)
eGFR, ml/min/1.73m2: mean (SD) 74 (17) 71 (17)
Serum total cholesterol, mmol/l: mean (SD) 5.2 (1.2) 5.0 (1.1)
Serum HDL cholesterol, mmol/l: mean (SD) 1.2 (0.3) 1.2 (0.3)
Serum LDL cholesterol, mmol/l: mean (SD) 3.1 (1.0) 2.9 (1.0)
Serum triglycerides, mmol/l: median (25th, 75th percentiles) 1.6 (1.2, 2.3) 1.6 (1.1, 2.3)
History of complications, n (%)
 Coronary arterial disease 2318 62 (2.6)
 Cerebrovascular disease 1401 38 (2.6)
 Diabetic kidney disease 2358 86 (3.5)
 Diabetic retinopathy 1041 38 (3.5)
 Dementia 107 2 (1.8)
History of tobacco smoking, n (%)
 Ever 4501 173 (3.7)
 Current 1626 56 (3.3)
History of alcohol drinking, n (%)
 Past 4097 140 (3.3)
 Current 3281 115 (3.4)
History of medication use, n (%)
Metformin 6582 170 (2.5)
 Insulin therapy 154 5 (3.1)
 Antihypertensive treatment 7448 207 (2.7)
 Antiplatelet drugs 5058 141 (2.7)




 Statins 3058 88 (2.8)
Study allocations, n (%)
 Intensive glucose control group 5423 148 (2.7)
 Perindopril/indapamide combination 5422 147 (2.6)
Categorical parameters are expressed as numbers (and percentages for participants who died from cancer causes)
ACR albumin to creatinine ratio. eGFR estimated Glomerular Filtration Rate computed by the Chronic Kidney Disease Epidemiology Collaboration equation. Mini-
Mental State Examination (MMSE) score: normal (≥ 28), reduced (< 28). Education accomplishment (age at completion of the highest level of formal education): basic 
(≥ 16 years), low (≤ 15 years)
Table 3 Risk of cancer death according to each individual parameter at baseline
Cox proportional hazards survival regressive analysis for each variable adjusted for study allocations. SD standard deviation
Hazard Ratio 95% CI p
Female sex 0.62 0.49–0.79  < 0.0001
Region of origin: established market economies (vs. Asia) 1.87 1.43–2.44  < 0.0001
Region of origin: Eastern Europe (vs. Asia) 1.68 1.21–2.33 0.002
Region of origin: established market economies (vs. Eastern Europe) 1.11 0.84–1.48 0.46
Age (per 1 SD increase) 1.82 1.63–2.03  < 0.0001
Duration of diabetes (per 1 SD increase) 1.01 0.91–1.13 0.83
Body mass index (per 1 SD increase) 1.08 0.97–1.20 0.14
Waist circumference (per 1 SD increase) 1.23 1.11–1.37  < 0.0001
Systolic blood pressure (per 1 SD increase) 1.07 0.96–1.19 0.23
Diastolic blood pressure (per 1 SD increase) 0.91 0.81–1.02 0.10
Mini-Mental State Examination score (< 28 vs. ≥ 28) 1.30 1.01–1.67 0.04
Education accomplishment (≤ 15 vs. ≥ 16 years) 1.44 1.15–1.80 0.001
HbA1c (per 1 SD increase) 1.04 0.93–1.16 0.45
Urinary albumin to creatinine ratio (per 1SD increase) 1.08 0.97–1.21 0.16
Estimated glomerular filtration rate (per 1 SD increase) 0.82 0.73–0.91 0.0003
Serum total cholesterol (per 1 SD increase) 0.85 0.75–0.95 0.007
Serum HDL cholesterol (per 1 SD increase) 0.88 0.78–0.99 0.03
Serum LDL cholesterol (per 1 SD increase) 0.84 0.75–0.95 0.004
Serum triglycerides (per 1 SD increase) 0.97 0.86–1.09 0.60
History of coronary arterial disease 0.91 0.69–1.20 0.52
History of cerebrovascular disease 0.96 0.68–1.34 0.79
History of diabetic kidney disease 1.38 1.08–1.77 0.01
History of diabetic retinopathy 1.34 0.96–1.89 0.09
History of dementia 0.63 0.16–2.52 0.51
History of current smoking 1.21 0.90–1.61 0.20
History of ever smoking 1.67 1.33–2.08  < 0.0001
History of past alcohol drinking 1.28 1.02–1.60 0.03
History of current alcohol drinking 1.27 1.01–1.60 0.04
Use of Metformin 0.75 0.60–0.93 0.01
Use of insulin therapy 1.17 0.48–2.83 0.72
Use of antihypertensive treatment 0.88 0.70–1.11 0.27
Use of antiplatelet drugs 0.92 0.74–1.15 0.48
Use of statins 0.95 0.75–1.22 0.71
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increased risk of all-cause, but not cardiovascular, death 
(Additional file  1: Table  S5). The association between 
lower-limb complications and cancer death did not 
change substantially when we considered death from 
non-cancer causes as a competing risk (Additional file 1: 
Table S5).
Risk of incident cancers according to history of lower‑limb 
complications at baseline
Incident cancers were diagnosed in 700 (6.3%) partici-
pants during follow-up (Additional file 1: Table S1), cor-
responding to 52,473 person-years and an incidence rate 
of 13.3 (95% CI, 12.4–14.4) per 1000 person-years. The 
cumulative incidences (Table  5) and incidence rates of 
cancers were higher in participants with a baseline his-
tory of lower-limb complication [17.1 (95% CI, 15.4–
19.0) vs.11.0 (9.9–12.2) per 1000 person-years], PAD 
[18.9 (16.5–21.6) vs. 11.8 (10.8–12.9) per 1000 person-
years] or peripheral neuropathy [16.7 (14.7–19.0) vs. 
12.1 (11.1–13.3) per 1000 person-years], compared with 
those without these conditions. The relative risk of inci-
dent cancers was higher in participants with (vs. with-
out) a baseline history of lower-limb complications [HR 
1.23 (1.05–1.44), p = 0.01] or PAD (1.20 (1.01–1.43), 
p = 0.04], but not those with peripheral neuropathy [1.14 
(0.97–1.35), p = 0.11] after adjustment for cofounding 
variables as in model 2 (Table 5). Association with PAD 
was particularly observed for solid and digestive malig-
nant neoplasms (Additional file 1: Table S6). Based on the 
alternative definitions of lower-limb complications, PAD 
remained associated with excess risk of incident cancers, 
while peripheral neuropathy and tissue or limb loss did 
not (Additional file  1: Table  S2). The history of diabetic 
neuropathy, defined as the presence of at least one neu-
rological abnormality or a history of foot ulceration, was 
not associated with the risk of incident cancers (Addi-
tional file 1: Table S3).
Discussion
In the present study, we investigated the relationship 
between a baseline history of lower-limb complications 
and the risk of cancer death in patients with type 2 dia-
betes in the ADVANCE study. We observed an inde-
pendent association between the history of lower-limb 
complications, both PAD and peripheral neuropathy, and 
excess 5-year risk of cancer death. No statistical interac-
tion was observed between PAD and sensory peripheral 
neuropathy in their association with the risk of cancer 
death. Our findings were reliable when we considered 
death from non-cancer causes as a competing risk. Of 
note, lower-limb complications and PAD were associated 
with increased risk of both all-cause and cardiovascular 
death, while neuropathy was associated with only all-
cause death. The history of PAD, but not peripheral neu-
ropathy, was also associated with a higher incidence of 
cancers, mainly solid and digestive neoplasms.
Lower‑limb complications and risk of cancer death
As far as we know, this is the first report of increased 
risk of cancer death related to lower-limb complications 
in patients with type 2 diabetes. Few previous studies 
reported increased incidence of cancers among patients 
with intermittent claudication or critical limb ischemia 
in general population [30, 31]. A recent study has shown 
an association between lower-limb arterial thrombosis 
and increased risk of subsequent cancers in 6600 patients 
(12% with diabetes) from Danish nationwide population-
based registries [32]. A lower-limb arterial thrombosis 
was also associated with a high risk of all-cause mortality 
following some site-specific (mainly smoking-dependent) 
cancers.
Table 4 Risk of cancer death according to history of lower-limb complications at baseline
Model 1: age (and its square), sex, region of origin, and study allocations
Model 2: model 1 plus duration of diabetes, body mass index (and its square), waist circumference (and its square), systolic and diastolic blood pressure (and their 
squares), HbA1c (and its square), urinary ACR, eGFR (and its square), total cholesterol, HDL cholesterol, triglycerides, MMSE score, education accomplishment, 
history of ever or current smoking, history of past or current alcohol drinking, history of CAD, cerebrovascular disease, diabetic retinopathy or dementia, and use of 
metformin, insulin, antihypertensive, statin or antiplatelet therapy
Cancer death, n (%) Model 1 Model 2
No, n Yes, n (%) Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Lower-limb complication No 6702 145 (2.1) 1.62 (1.29–2.04)  < 0.0001 1.53 (1.21–1.94) 0.0004
Yes 4122 171 (4.0)
Peripheral arterial disease No 8488 213 (2.4) 1.43 (1.12–1.83) 0.004 1.32 (1.02–1.70) 0.03
Yes 2336 103 (4.2)
Peripheral neuropathy No 7971 196 (2.4) 1.49 (1.19–1.88) 0.0006 1.41 (1.11–1.79) 0.004
Yes 2853 120 (4.0)
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Potential mechanisms linking lower‑limb complications 
to cancer death
Our findings cannot allow any etiological conclusion, 
and may only suggest lower-limb complications as proxy 
for cancer death. Indeed, lower-limb complications are 
surrogates for advanced microvascular and macrovas-
cular disease, and may lead to a greater likelihood of 
multisystem disease. Nevertheless, lower-limb compli-
cations and malignancies may share some modifiable 
risk factors, including age, obesity and tobacco smoking 
[33–35]. These risk factors are unlikely to explain our 
findings as the key observed associations were reliable 
after adjustment for these confounders. Furthermore, 
the magnitude of the associations between lower-limb 
complications and cancer death were comparable when 
we performed analyses in people who have smoked ciga-
rettes regularly and those who have never smoked, with-
out evidence for statistical interaction. Further studies 
are needed to investigate the potential contribution of 
smoking in the relationship between lower-limb com-
plications and cancer death. Lower-limb complications 
and malignancies may also share some common biologi-
cal disorders including chronic inflammation, increased 
advanced glycation endproducts and oxidative stress 
[36–39]. Oxidative stress leads to lipid peroxidation and 
DNA damage, which are involved in microvascular dis-
ease, atherosclerosis and cancer [36, 40]. Furthermore, 
endothelial dysfunction, an important impairment 
involved in lower-limb complications, has also been 
linked to increased risk of solid-tumor cancer [41]. While 
lower-limb complications, involving microvascular dis-
ease and atherosclerosis (as a result at least partly of early 
endothelial dysfunction), cancer is mainly character-
ized by excessive angiogenesis, which may be driven by 
endothelial metabolic aberrations [42].
Effects of glucose and blood pressure controls in risk 
of cancer death
We did not observe an association between ADVANCE 
allocation to blood pressure treatment and the risk of 
cancer death, as was previously reported for intensive 
glucose control [28]. However, we have observed a non-
significant decrease in risk of cancer death in participants 
assigned to both glucose control and blood pressure 
interventions, compared with those allocated to con-
ventional glucose control and placebo blood pressure 
treatments. This observation may raise the hypothesis 
wondering the potential effect of multifactorial inter-
vention on the incidence of cancer death in people with 
type 2 diabetes. Randomised clinical trials are required to 
address this hypothesis. Of note, Rasmussen-Torvik and 
coworkers reported an inverse association between the 
number of ideal cardiovascular health metrics, as defined 
by the American Heart Association [43] (including blood 
pressure and glycemia) and combined cancer incidence 
in the Atherosclerosis Risk In Communities (ARIC) 
cohort [44].
Strengths and limitations
The main strength of our work is the use of a large inter-
national multicentre study of 11,140 patients with type 
2 diabetes, with a comprehensive range of data includ-
ing demographic, clinical and biological features at 
baseline. Participants were also prospectively followed 
Fig. 1 Cumulative incidence of cancer death during follow-up 
according to history of lower-limb complications at baseline. Solid 
line: absence of complication; dashed line: presence of complication. 
P values (log-rank test) for comparing absence and presence < 0.0001 
for all three complications. LLC lower-limb complications, PAD 
peripheral artery disease
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for 5  years, with adjudicated causes of mortality, 
including cancer death within a central and independ-
ent adjudication committee process. However, inci-
dent cancers were collected from case report forms and 
reports of serious adverse events, without adjudication 
or validation using cancer registry data. The other limi-
tation of our study is related to the post hoc analyses 
of a randomized controlled trial, and the use of a clini-
cal trial population, which may not be representative of 
all patients with type 2 diabetes. Also, we used a prag-
matic assessment of lower-limb complications without 
a prespecified research protocol, and we missed some 
data regarding PAD (intermittent claudication, ankle 
brachial index, toe pressure or transcutaneous oxygen 
pressure) or peripheral sensory neuropathy (symptoms 
or vibration sensation test). We do not believe that 
these issues influenced our findings as we investigated a 
widespread spectrum of data including clinical exami-
nation (pulses palpation, light touch sensation and 
reflex tests), condition (foot ulceration) and procedures 
(revascularisation and lower-extremity amputation). 
However, we cannot exclude that non-diabetic causes 
of neuropathy could have biased our findings, especially 
neurotoxicity of cancer treatment (chemotherapeu-
tic drugs and radiotherapy), paraneoplastic neurologic 
disorders or nervous dysfunction caused by the cancer 
[45]. Nevertheless, cancer-related neuropathy seemed 
to be unlikely, since we dealt with a high prevalent neu-
ropathy (n = 2973, 27%) consistent with diabetic origin, 
while incident cancers were diagnosed only in 700 (6%) 
participants. Finally, our findings were not controlled 
for socioeconomic position as we missed appropriate 
data, except for education accomplishment.
Conclusions
In summary, our study links PAD and sensory periph-
eral neuropathy to excess 5-year risk for cancer death 
in patients with type 2 diabetes. In addition, PAD was 
also associated with increased risk of incident cancers, 
especially solid and digestive ones. Our findings pro-
vide new evidence on the non-cardiovascular prognos-
tic burden of lower-limb complications in people with 
type 2 diabetes, and encourage continuing careful eval-
uation and management of cancers in this population.
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